Successful obinutuzumab administration after rituximab discontinuation due to intolerance in patients with hematologic disorders.
Saved in:
| Title: | Successful obinutuzumab administration after rituximab discontinuation due to intolerance in patients with hematologic disorders. |
|---|---|
| Authors: | Schieber T; Department of Pharmacy, James Cancer Hospital and Solove Research Institute at The Ohio State University, Columbus, OH., Li A; Department of Pharmacy, James Cancer Hospital and Solove Research Institute at The Ohio State University, Columbus, OH., Lundberg J; Department of Pharmacy, James Cancer Hospital and Solove Research Institute at The Ohio State University, Columbus, OH., Wiczer T; Department of Pharmacy, James Cancer Hospital and Solove Research Institute at The Ohio State University, Columbus, OH., Voorhees T; Department of Medicine-Hematology, James Cancer Hospital and Solove Research Institute at The Ohio State University, Columbus, OH. |
| Source: | Blood advances [Blood Adv] 2023 Jul 25; Vol. 7 (14), pp. 3431-3434. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 2473-9537 |
|---|---|
| DOI: | 10.1182/bloodadvances.2022009548 |
